Victoria Reich
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RBC and Citi highlight Ecolab's pricing power and specialty chemical strength. Recent analyst notes from RBC Capital Markets and Citi have focused on Ecolab's ability to maintain pricing and organic growth. These firms view the company as a defensive option that may benefit from a weaker dollar. The positive sentiment aligns with the stock trading near its 52-week high, reflecting strong investor interest in its stable earnings profile.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
HRB Featured in Recent Dividend and Growth Stock Lists. SeekingAlpha called HRB a stable business with attractive returns. A dividend champion article highlighted HRB as a contender for dividend-focused investors. A Yahoo piece on bookkeeping and payroll underscored the relevance of HRB’s core services in the current market.
Transaction History
| INGR | ▲ Buy | Grant | 1,797 | $193K | 5/20/2026 | View on chart |
| ECL | ▲ Buy | Grant | 138 | $0 | 3/31/2026 | View on chart |
| INGR | ▲ Buy | Grant | 380 | $43K | 3/31/2026 | View on chart |
| ECL | ▼ Sell | Open Market | 1,000 | $301K | 2/13/2026 | View on chart |
| ECL | ▲ Buy | Option Exercise | 1,000 | $115K | 2/13/2026 | View on chart |
| ECL | ▲ Buy | Grant | 128 | $0 | 12/31/2025 | View on chart |
| INGR | ▲ Buy | Grant | 371 | $40K | 12/5/2025 | View on chart |
| HRB | ▲ Buy | Grant | 3,927 | $0 | 11/5/2025 | View on chart |
| ECL | ▲ Buy | Grant | 123 | $0 | 9/30/2025 | View on chart |
| INGR | ▲ Buy | Grant | 321 | $40K | 9/30/2025 | View on chart |
| ECL | ▲ Buy | Grant | 126 | $0 | 6/30/2025 | View on chart |
| INGR | ▲ Buy | Grant | 291 | $40K | 6/30/2025 | View on chart |
| ECL | ▼ Sell | Open Market | 1,300 | $352K | 6/12/2025 | View on chart |
| ECL | ▲ Buy | Option Exercise | 1,300 | $150K | 6/12/2025 | View on chart |
| ECL | ▲ Buy | Grant | 134 | $0 | 3/31/2025 | View on chart |
| INGR | ▲ Buy | Grant | 302 | $40K | 3/31/2025 | View on chart |
| ECL | ▲ Buy | Grant | 144 | $0 | 12/31/2024 | View on chart |
| INGR | ▲ Buy | Grant | 275 | $40K | 12/12/2024 | View on chart |
| HRB | ▲ Buy | Grant | 3,148 | $0 | 11/6/2024 | View on chart |
| INGR | ▲ Buy | Grant | 295 | $40K | 9/30/2024 | View on chart |
| ECL | ▲ Buy | Grant | 133 | $0 | 9/30/2024 | View on chart |
| ECL | ▼ Sell | Open Market | 393 | $98K | 9/12/2024 | View on chart |
| ECL | ▲ Buy | Option Exercise | 393 | $44K | 9/12/2024 | View on chart |
| ECL | ▲ Buy | Option Exercise | 1,807 | $204K | 9/11/2024 | View on chart |
| ECL | ▼ Sell | Open Market | 1,807 | $452K | 9/11/2024 | View on chart |
| ECL | ▲ Buy | Grant | 141 | $0 | 6/30/2024 | View on chart |
| INGR | ▲ Buy | Grant | 347 | $40K | 6/28/2024 | View on chart |
| ECL | ▲ Buy | Grant | 146 | $0 | 3/31/2024 | View on chart |
| INGR | ▲ Buy | Grant | 342 | $40K | 3/29/2024 | View on chart |
| ECL | ▲ Buy | Grant | 157 | $0 | 12/31/2023 | View on chart |
| INGR | ▲ Buy | Grant | 361 | $38K | 12/11/2023 | View on chart |
| HRB | ▲ Buy | Grant | 4,540 | $0 | 11/3/2023 | View on chart |
| ECL | ▲ Buy | Grant | 184 | $0 | 9/30/2023 | View on chart |
| INGR | ▲ Buy | Grant | 377 | $37K | 9/29/2023 | View on chart |
| ECL | ▲ Buy | Grant | 168 | $0 | 6/30/2023 | View on chart |
| INGR | ▲ Buy | Grant | 354 | $38K | 6/30/2023 | View on chart |
| ECL | ▲ Buy | Grant | 190 | $0 | 3/31/2023 | View on chart |
| INGR | ▲ Buy | Grant | 381 | $37K | 3/31/2023 | View on chart |
| ECL | ▲ Buy | Grant | 215 | $0 | 12/31/2022 | View on chart |
| HRB | ▲ Buy | Grant | 4,679 | $0 | 11/4/2022 | View on chart |
| INGR | ▲ Buy | Grant | 488 | $40K | 10/3/2022 | View on chart |
| ECL | ▲ Buy | Grant | 214 | $0 | 9/30/2022 | View on chart |
| INGR | ▲ Buy | Grant | 458 | $41K | 7/1/2022 | View on chart |
| ECL | ▲ Buy | Grant | 205 | $0 | 6/30/2022 | View on chart |
| INGR | ▲ Buy | Grant | 475 | $41K | 4/1/2022 | View on chart |
| ECL | ▲ Buy | Grant | 175 | $0 | 3/31/2022 | View on chart |
| INGR | ▲ Buy | Grant | 424 | $41K | 1/3/2022 | View on chart |
| ECL | ▲ Buy | Grant | 123 | $0 | 12/31/2021 | View on chart |
| ECL | ▲ Buy | Option Exercise | 2,400 | $252K | 11/10/2021 | View on chart |
| ECL | ▼ Sell | Open Market | 2,400 | $560K | 11/10/2021 | View on chart |
| INGR | ▲ Buy | Grant | 394 | $36K | 10/1/2021 | View on chart |
| ECL | ▲ Buy | Grant | 136 | $0 | 9/30/2021 | View on chart |
| ECL | ▲ Buy | Option Exercise | 3,200 | $270K | 9/8/2021 | View on chart |
| ECL | ▲ Buy | Option Exercise | 1,300 | $83K | 9/8/2021 | View on chart |
| ECL | ▼ Sell | Open Market | 4,500 | $1.0M | 9/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ingredion Sees Rising Clean-Label Demand, UBS Lowers Target
Demand for clean‑label ingredients is growing, which has helped lift Ingredion’s share price. UBS kept a neutral stance but cut its price target to $104, citing uncertainty about future momentum. The company’s T&HS solutions are being examined for their ability to sustain growth into 2026.
Ingredion Sees Rising Clean-Label Demand, UBS Lowers Target. Demand for clean‑label ingredients is growing, which has helped lift Ingredion’s share price. UBS kept a neutral stance but cut its price target to $104, citing uncertainty about future momentum. The company’s T&HS solutions are being examined for their ability to sustain growth into 2026.